Alkem completes Rs 1,079.76 crore Occlutech control deal

Alkem Laboratories Limited completed its acquisition of a 55% controlling stake in Occlutech Holding AG on 16 July 2026 for Rs 1,079.76 crore, creating a separately reported MedTech segment that recorded Rs 133.14 crore of revenue and a Rs 49.63 crore loss in the quarter ended 30 September 2026.

What did Alkem acquire in Occlutech?

Alkem acquired a 55% equity stake and controlling interest in Occlutech through Alkem Medtech Private Limited, its wholly owned subsidiary, on 16 July 2026. The fair-value consideration was Rs 1,079.76 crore, subject to adjustments under the share purchase agreement, and the transaction was accounted for as a business combination under Indian Accounting Standard 103, or Ind AS 103.

The consideration comprised Rs 877.83 crore of cash and Rs 201.93 crore of deferred consideration. In the six months ended 30 September 2026, Alkem reported Rs 808.04 crore of net cash used for business acquisitions, compared with Rs 171.49 crore in the corresponding six months of 2025. That cash-flow line covers business acquisitions and is not presented as a transaction-specific reconciliation.

Alkem reassessed its reportable operating segments after gaining control in July 2026. The group now reports Pharmaceuticals, Biotech and MedTech as segments based on information reviewed by its Chief Operating Decision Maker. Prior-period segment information has been presented using the revised structure to facilitate comparison under Indian Accounting Standard 108, or Ind AS 108.

How was the Occlutech purchase price accounted for?

Alkem provisionally recognised Rs 1,604.78 crore of identifiable assets and Rs 920.86 crore of liabilities from the acquisition, producing Rs 703.60 crore of goodwill. The acquired liabilities included a Rs 172.40 crore deferred-tax liability. The purchase price allocation remains provisional under the measurement-period provisions of Ind AS 103.

The acquisition accounting coincided with a sharp increase in certain consolidated non-current asset categories between 31 March 2026 and 30 September 2026. Goodwill rose from Rs 523.64 crore to Rs 1,221.02 crore, while other intangible assets rose from Rs 256.76 crore to Rs 1,360.76 crore. Total non-current assets increased from Rs 8,662.45 crore to Rs 10,077.50 crore.

Alkem will finalise the purchase price allocation within the measurement period permitted by Ind AS 103. Any adjustments will be recognised retrospectively from the acquisition date of 16 July 2026. As a result, the provisional values for goodwill, acquired assets and acquired liabilities could change in later financial statements.

How did MedTech perform after the Occlutech acquisition?

MedTech generated Rs 133.14 crore of revenue in the quarter ended 30 September 2026 and recorded a segment loss of Rs 49.63 crore. Revenue was Rs 7.65 crore in the preceding June 2026 quarter and Rs 2.70 crore in the September 2025 quarter, while the segment loss was Rs 12.25 crore and Rs 6.31 crore respectively.

For the six months ended 30 September 2026, MedTech revenue was Rs 140.79 crore, compared with Rs 5.06 crore in the corresponding 2025 period. Its six-month segment loss widened to Rs 61.88 crore from Rs 12.48 crore. The September quarter was the first reported quarter following the 16 July 2026 completion of the controlling-interest acquisition.

MedTech segment assets were Rs 2,486.34 crore at 30 September 2026, up from Rs 375.52 crore at 31 March 2026 and Rs 306.02 crore a year earlier. MedTech segment liabilities increased to Rs 333.07 crore from Rs 72.90 crore at 31 March 2026. The segment asset change followed the consolidation of Occlutech and related acquisition accounting.

What changed in Alkem’s consolidated financial position?

Alkem’s total consolidated assets increased to Rs 23,059.64 crore at 30 September 2026 from Rs 20,872.97 crore at 31 March 2026. Total liabilities rose to Rs 7,370.64 crore from Rs 6,524.04 crore over the same period. Non-current borrowings increased from Rs 492.45 crore to Rs 1,033.46 crore, while current borrowings declined from Rs 1,131.05 crore to Rs 829.60 crore.

Consolidated revenue from operations reached Rs 4,551.99 crore in the September 2026 quarter, compared with Rs 4,000.99 crore a year earlier. Pharmaceuticals generated Rs 4,347.92 crore of segment revenue, compared with Rs 133.14 crore from MedTech and Rs 129.79 crore from Biotech, before Rs 58.86 crore of inter-segment revenue was eliminated.

Consolidated profit for the September 2026 quarter was Rs 667.13 crore, down from Rs 779.11 crore a year earlier, although profit before tax rose to Rs 999.65 crore from Rs 895.83 crore. The quarter included a Rs 35 crore exceptional recovery against an investment impaired during the quarter and year ended 31 March 2026. Finance costs increased to Rs 57.67 crore from Rs 35.02 crore, while depreciation and amortisation rose to Rs 137.08 crore from Rs 93.61 crore.

Conclusion

Alkem’s control acquisition of Occlutech established MedTech as a separate reporting segment and added Rs 703.60 crore of provisional goodwill to the consolidated balance sheet. MedTech contributed Rs 133.14 crore of September-quarter revenue, but reported a Rs 49.63 crore segment loss, while Pharmaceuticals remained the group’s largest business with Rs 4,347.92 crore of quarterly segment revenue.

The next disclosed accounting event is finalisation of the purchase price allocation within the Ind AS 103 measurement period, with any changes recognised retrospectively from 16 July 2026. Subsequent quarterly disclosures will also show whether MedTech revenue continues beyond the Rs 133.14 crore reported after the acquisition and whether its segment loss changes as the business is consolidated for a full period.